YOYasuyuki Ohta

Yasuyuki Ohta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yasuyuki Ohta has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Koji Abe

    Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan

    4 shared publications
  • Isao Nagano

    Department of Neurology, Graduate School of Medicine, Dentistry and Pharmacy, Okayama University

    2 shared publications
  • Mikio Shoji

    Hirosaki University

    2 shared publications
  • Yasushi Takehisa

    Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan

    2 shared publications
  • Daigo Niiya

    Department of Internal Medicine, Okayama Rousai Hospital, Okayama, Japan

    1 shared publication
  • Hideki Fujioka

    Department of Internal Medicine, Okayama Rousai Hospital, Okayama, Japan

    1 shared publication

Latest Publications

  • Open Access

    Early Detachment of Neuromuscular Junction Proteins in Als Mice with Sodg93a Mutation

    by Hisashi Narai, Yasuhiro Manabe, Makiko Nagai, Isao Nagano, Yasuyuki Ohta, Tetsuro Murakami, Yasushi Takehisa, Tatsushi Kamiya, Koji Abe

    The transgenic animals with mutant copper/zinc superoxide dismutase (SOD1) DNA develop paralytic motor neuron disease resembling human amyotrophic lateral sclerosis (ALS) patients and are commonly used as models for ALS. In the transgenic (Tg) mice with the G93A mutation of the human SOD1 gene (SOD1G93A mice), the loss of ventral root axons and the synapses between the muscles and the motor neurons suggested that the motor neuron degeneration might proceed in a dying-back degeneration pattern. To reveal the relationship between axonal degeneration and the progression of the muscle atrophy in the SOD1G93A mice, we investigated the status of the neuromuscular junction along the disease progression. As a presynaptic or postsynaptic marker of neuromuscular junction (NMJ), anti-synaptic vesicle protein 2 (anti-SV2) antibody and a-bungarotoxin (a-BuTX ) were chosen in this study and, as a marker of synaptic cleft, anti-agrin antibody was chosen in this study. In the immunohistochemistry of a-BuTX and anti-SV2 antibody, the percentages of double positive NMJs among a-BuTX single positive were decreased in Tg mice through time from ten weeks. The number of postsynaptic acethylcholine receptor (AChR) clusters did not decrease in Tg mice even at the end stage. Immunohistochemistry of a-BuTX and anti-agrin antibody revealed that the increase of immunopositive area of anti-agrin antibody around the muscle fiber in Tg mice from ten weeks of age. In this study, we revealed that the detachment of nerve terminals started at ten weeks in Tg mice. The levels of AChR did not change throughout 5-20 weeks of age in both groups of mice, and AChR remains clustering at NMJs, suggesting that the muscle abnormality is the result of detachment of nerve terminals.


  • Open Access

    Efficacy of the Free Radical Scavenger, Edaravone, for Motor Palsy of Acute Lacunar Infarction

    by Yasuyuki Ohta, Kazuhiro Takamatsu, Tomoko Fukushima, Satomi Ikegami, Ikuko Takeda, Taisei Ota, Katsuya Goto, Koji Abe

    Objective Free radicals are important in causing neural cell injury during cerebral infarction. Although there was a randomized, placebo-controlled, double-blind study at multiple centers in Japan showing the efficacy of the free radical scavenger, edaravone, in acute cerebral infarction, to date the clinical studies are few. This study investigated the effect of edaravone on the outcome of patients with acute lacunar infarction. Methods We retrospectively evaluated 124 consecutive patients with first-ever acute lacunar infarctions who were admitted to our hospital within 24 hours after the onset between January 2004 and June 2007. Of these, 59 patients received both edaravone and conventional therapy (edaravone group), and the other 65 underwent conventional therapy only (non-edaravone group). There was no significant difference in patients' baseline characteristics in the two groups. The clinical outcome was assessed by the National Institutes of Health Stroke Scale (NIHSS). Results The reduction of NIHSS scale during hospitalization (1.5±1.0 vs. 1.0±1.1; p = 0.007), especially that of the motor palsy scale (1.0±1.0 vs. 0.5±1.0; p = 0.006) was significantly larger, and the percentage of patients with a favorable outcome (NIHSS at discharge ≤1) (91.5% vs. 78.5%; p = 0.044) was significantly better in the edaravone group. Conclusion Edaravone improves the outcomes of patients with acute lacunar infarction, especially motor palsy, without regard to the conventional therapy performed concomitantly.


  • Open Access

    Two Cases of Spinocerebellar Ataxia Accompanied by Involvement of the Skeletal Motor Neuron System and Bulbar Palsy

    by Yasuyuki Ohta, Takeshi Hayashi, Makiko Nagai, Miyuki Okamoto, Shoko Nagotani, Isao Nagano, Nobuhiko Ohmori, Yasushi Takehisa, Tetsuro Murakami, Mikio Shoji, et al.

    We report two patients with spinocerebellar ataxia (SCA) with cranial and spinal motor neuron involvement. They initially presented with cerebellar ataxia, followed by bulbar palsy and limb motor neuron sign. One of the patients had a brother with allied disorder. SCA type 1 (SCA1), SCA3 and SCA6 have been reported to involve the motor neuron system, but they were excluded by DNA analyses in the present two patients. These two patients may form a distinct disease entity among SCAs.


  • Nonparaneoplastic limbic encephalitis with relapsing polychondritis

    by Yasuyuki Ohta, Isao Nagano, Daigo Niiya, Hideki Fujioka, Takumi Kishimoto, Mikio Shoji, Koji Abe